Research Funding Opportunities
$8 Million SU2C-Lustgarten Foundation Pancreatic Cancer Convergence Dream Team Translational Research Grant
Application Due Date: November 7, 2013
The American Association for Cancer Research (AACR) is now accepting submissions of ideas for the Stand Up To Cancer (SU2C)-Lustgarten Foundation Pancreatic Cancer Convergence Dream Team Translational Research Grant, which will offer up to $8 million over a three-year period.
Nobel laureate Phillip A. Sharp, Ph.D., describes convergence research as an exciting new approach that brings together the biological, computational, physical, and engineering sciences and entails not only collaboration among research groups, but also the integration of disciplinary approaches that were originally viewed as separate and distinct.
The grant provides three years of funding for research projects that must include therapeutic interventions for pancreatic cancer and deliver near-term patient benefit through investigation by a multidisciplinary, multi-institutional Convergence Dream Team of experts. The project must bring together biology (e.g. genomics, epigenetics, proteomics, and/or other biological fields) and at least one additional field of research such as physics, engineering, or immunology.
Letters of Intent for SU2C-Lustgarten Foundation Pancreatic Cancer Convergence Dream Team Translational Research Grant projects are due by noon ET on Nov. 7, 2013, via proposalCENTRAL at https://proposalcentral.altum.com. For general information on eligibility criteria, the application process, and other details about this Dream Team grant, visit www.AACR.org/SU2CFunding. Inquiries may be directed to the AACR Scientific Review and Grants Administration Department at 267-765-1049 or firstname.lastname@example.org. The SU2C-Lustgarten Foundation Pancreatic Cancer Convergence Dream Team Translational Research Grant recipients are scheduled to be announced in spring 2014. Read the full press release.
2013 Correlative Concepts Now Being Accepted
Application Due Date: December 12, 2013
The Lustgarten Foundation (LF) will review Correlative Letters of intent associated with approved and funded clinical trials including those funded by CTEP. The correlative studies proposed should be based on strong and testable hypotheses. A clear rationale should be given for the experimental design and technical methodologies selected. The hypotheses tested must relate to potential clinical applications such as patient monitoring for preventive or therapeutic interventions, development of new therapeutic strategies, and/or testing new biomarkers for the identification of patient subsets for specific prevention or treatment approaches. Applications must include a statistical section describing the study design and plans for analysis of data designed to test the hypotheses. While single center studies are acceptable, investigators are encouraged to work with muli-institutional organizations of form a consortium in order to both access sufficient numbers of patient specimens as well as ensure that assays are carried out in the most appropriate environment.
How to Apply/Deadlines
The LF has modified its application process to allow for electronic concept and full application submission. Information on how to use this site can be found in our Applicant Tutorial.